Prostama · 20MG

Prostamax (also referred to as Libidon in some Khavinson literature) is a short-chain peptide bioregulator in the Khavinson cytomedin / cytogen class — synthetic short peptides developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, proposed to function through tissue-specific gene expression modulation. Prostamax is described as the prostate tissue-derived bioregulator within this peptide family. Some Russian academic sources report the active compound as the tetrapeptide Lys-Glu-Asp-Pro (KEDP), though the chemistry is less rigorously documented in Western scientific literature than the major characterized Khavinson peptides (Epithalon, Cortagen, Pinealon, Chonluten, Pancreagen). The compound is investigated in preclinical research as a representative of the broader Khavinson short-peptide bioregulator class for tissue-specific peptide pharmacology and comparative SAR studies. Researchers working with this compound should verify the specific chemistry against the supplier's Certificate of Analysis (COA) and rely on MS-verified molecular weight as the primary identity confirmation.

Benefits (Research Focus)

• Khavinson cytomedin research — studied as a representative compound for tissue-specific peptide bioregulator pharmacology

• Cellular gene expression — investigated for gene expression endpoints in cell culture research models

• Comparative SAR research — explored alongside other Khavinson short-peptide bioregulators for structure-activity studies

• Tissue-specific peptide signaling — examined as a "cytomedin" class compound for tissue-selective gene expression research

• Geroscience research — researched for cellular aging endpoints in epithelial cell research models

What Researchers Look At

• Gene expression panels and cellular signaling in epithelial cell research models

• Comparative pharmacology versus characterized Khavinson peptides (Epithalon, Cortagen, etc.)

• Tissue-selective peptide uptake and cellular response patterns

• Molecular weight characterization and MS-based identity verification

• Aged-tissue versus young-tissue model responses in comparative cellular research

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Prostamax

• Synonyms: Libidon (in some Khavinson literature); Khavinson-tradition prostate peptide bioregulator

• Class: Short-chain peptide bioregulator; Khavinson-tradition cytomedin / cytogen class

• Reported sequence: Lys-Glu-Asp-Pro (KEDP) per some Russian sources — verify against batch COA

• Origin: Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology (Russia)

• Molecular Weight: Low molecular weight peptide, reported in the ~400–600 Da range (verify against batch COA — KEDP would correspond to ~458 Da)

• CAS: Not formally assigned (peptide bioregulator class)

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Prostamax COA — May 28, 2026